Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dyax's HAE drug succeeds in second Phase III trial

This article was originally published in Scrip

Executive Summary

Dyax's lead investigational hereditary angioedema (HAE) drug DX-88 (ecallantide) has met the primary endpoint of its second Phase III trial, and the company intends to submit a BLA to the FDA early in the fourth quarter of 2008. Shares in the US-based biotech company rose 15% on the news of the trial results, closing at $5.00 on Nasdaq on August 18th.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts